

Manolo Carta

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7798854/manolo-carta-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

4,121
citations

32
h-index

64
g-index

68
ext. papers

4,519
ext. citations

5.2
avg, IF

5.03
L-index

#	Paper	IF	Citations
67	Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. <i>Brain</i> , 2007 , 130, 1819-33	11.2	509
66	Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. <i>Journal of Neuroscience</i> , 2007 , 27, 6995-7005	6.6	352
65	Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. <i>Stem Cells</i> , 2006 , 24, 1433-40	5.8	337
64	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015 , 132, 96-168	10.9	282
63	Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. <i>Journal of Neuroscience</i> , 2009 , 29, 15923-32	6.6	259
62	Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. <i>Brain</i> , 2008 , 131, 3380-94	11.2	201
61	Vitamin A deficiency produces spatial learning and memory impairment in rats. <i>Neuroscience</i> , 2002 , 115, 475-82	3.9	171
60	Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. <i>Journal of Neuroscience</i> , 2007 , 27, 8011-22	6.6	161
59	Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. <i>Neurobiology of Disease</i> , 2004 , 17, 219-36	7.5	131
58	Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. <i>Journal of Neurochemistry</i> , 2006 , 96, 1718-27	6	128
57	Study of the antidyskinetic effect of eltopazine in animal models of levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2013 , 28, 1088-96	7	114
56	Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. <i>Progress in Brain Research</i> , 2008 , 172, 465-78	2.9	96
55	Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. <i>Neuroscience</i> , 2011 , 198, 245-51	3.9	87
54	Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. <i>Experimental Neurology</i> , 2009 , 219, 298-307	5.7	79
53	Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. <i>Brain</i> , 2009 , 132, 319-35	11.2	74
52	Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. <i>Neurobiology of Disease</i> , 2006 , 23, 522-32	7.5	65
51	Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S174-9	7	56

50	The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. <i>Molecular and Cellular Neurosciences</i> , 2008 , 37, 335-45	4.8	56
49	Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. <i>Journal of Neuroscience</i> , 2010 , 30, 11043-56	6.6	53
48	Involvement of the serotonin system in L-dopa-induced dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2008 , 14 Suppl 2, S154-8	3.6	50
47	Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations. <i>Frontiers in Neurology</i> , 2014 , 5, 78	4.1	46
46	Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2014 , 257, 25-38	5.7	43
45	Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. <i>Neuroscience Research</i> , 2013 , 77, 242-6	2.9	41
44	BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. <i>Experimental Neurology</i> , 2017 , 297, 73-81	5.7	41
43	5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. <i>Neurobiology of Disease</i> , 2013 , 60, 108-14	7.5	40
42	Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats. <i>Neuroscience</i> , 2006 , 139, 1163-72	3.9	40
41	Modulation of serotonergic transmission by eltopazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. <i>Neurobiology of Disease</i> , 2016 , 86, 140-53	7.5	37
40	Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2012 , 47, 393-406	7.5	36
39	Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease. <i>Neuroscience</i> , 2015 , 298, 389-96	3.9	35
38	Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. <i>Brain</i> , 2010 , 133, 496-511	11.2	35
37	Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia. <i>Experimental Neurology</i> , 2011 , 232, 240-50	5.7	34
36	Biphasic effects of ethanol on acetylcholine release in the rat prefrontal cortex. <i>Brain Research</i> , 2004 , 997, 128-32	3.7	34
35	Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 501-11	7	30
34	Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. <i>Neuroscience</i> , 2014 , 265, 245-52	3.9	27
33	The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective. <i>Journal of Neural Transmission</i> , 2018 , 125, 1195-1202	4.3	23

32	Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant mice. <i>Molecular and Cellular Neurosciences</i> , 2006 , 31, 293-302	4.8	23
31	Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. <i>Neuroscience Research</i> , 2012 , 73, 168-72	2.9	21
30	5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. <i>Neurobiology of Disease</i> , 2019 , 121, 120-130	7.5	21
29	A simple method for large-scale generation of dopamine neurons from human embryonic stem cells. <i>Journal of Neuroscience Research</i> , 2010 , 88, 3467-78	4.4	19
28	L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2011 , 11, 305-20	1.8	19
27	The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. <i>Scientific Reports</i> , 2019 , 9, 8898	4.9	18
26	Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats. <i>Behavioural Brain Research</i> , 2015 , 292, 300-4	3.4	18
25	The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation. <i>Neurobiology of Disease</i> , 2014 , 62, 233-40	7.5	15
24	A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease. <i>European Journal of Pharmacology</i> , 2017 , 813, 10-16	5.3	14
23	Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?. <i>Brain</i> , 2015 , 138, 829-30	11.2	14
22	Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. <i>Journal of Neurochemistry</i> , 2009 , 111, 355-67	6	14
21	Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine. <i>Brain Research</i> , 2006 , 1094, 86-91	3.7	13
20	The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2017 , 291, 1-7	5.7	12
19	Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia. <i>Parkinson's Disease</i> , 2015 , 2015, 563820	2.6	11
18	VGF peptides as novel biomarkers in Parkinson's disease. <i>Cell and Tissue Research</i> , 2020 , 379, 93-107	4.2	9
17	Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease. <i>Parkinson's Disease</i> , 2012 , 2012, 370190	2.6	8
16	Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats. <i>Psychopharmacology</i> , 2008 , 198, 191-200	4.7	8
15	5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation. <i>Basal Ganglia</i> , 2013 , 3, 9-13		7

14	Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 374, 113-125	4.7	6
13	Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. <i>European Journal of Neurology</i> , 2020 , 27, 779-786	6	6
12	Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding. <i>Journal of the Neurological Sciences</i> , 2020 , 415, 116869	3.2	6
11	Vitamin A deficiency affects neither frontocortical acetylcholine nor working memory. <i>NeuroReport</i> , 2007 , 18, 241-3	1.7	6
10	Augmented cocaine-induced accumbal dopamine efflux, motor activity and place preference in rats fed with a tryptophan-deficient diet. <i>Neuroscience Letters</i> , 2006 , 401, 125-9	3.3	6
9	BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 1503-1514	5.3	5
8	Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020 , 153, 102053	2.8	4
7	Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT(1A), but not 5-HT _{2A} receptor activation. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1329-35	1.2	4
6	Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update. <i>Progress in Brain Research</i> , 2021 , 261, 287-302	2.9	4
5	Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease. <i>Sleep and Breathing</i> , 2021 , 1	3.1	4
4	On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats. <i>Movement Disorders</i> , 2016 , 31, 149	7	2
3	Amphetamine Usage, Misuse, and Addiction Processes: An Overview 2016 , 14-24		1
2	Assessment of Nonmotor Symptoms in Rodent Models of Parkinson's Disease. <i>Neuromethods</i> , 2021 , 21-36	0.4	
1	The Serotonergic System in Levodopa-Induced Dyskinesia 2014 , 199-212		